Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Reiterated by Canaccord Genuity Group

Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “buy” rating reiterated by equities research analysts at Canaccord Genuity Group in a research note issued to investors on Thursday, Benzinga reports. They currently have a $1,152.00 target price on the biopharmaceutical company’s stock. Canaccord Genuity Group’s target price would indicate a potential upside of 9.61% from the stock’s previous close.

REGN has been the topic of several other reports. TD Cowen lifted their price objective on Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. Argus lifted their price objective on Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the company a “buy” rating in a research report on Tuesday. Evercore ISI began coverage on Regeneron Pharmaceuticals in a research report on Tuesday, May 14th. They issued an “outperform” rating and a $1,150.00 price target on the stock. UBS Group boosted their price target on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a “buy” rating in a research report on Wednesday, April 17th. Finally, StockNews.com cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, April 30th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $1,027.55.

Regeneron Pharmaceuticals Stock Up 0.0 %

Shares of NASDAQ:REGN opened at $1,051.03 on Thursday. The stock’s 50-day moving average is $984.27 and its 200 day moving average is $950.40. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.27 and a quick ratio of 4.51. The company has a market cap of $115.81 billion, a PE ratio of 31.05, a P/E/G ratio of 2.21 and a beta of 0.13. Regeneron Pharmaceuticals has a 1 year low of $688.52 and a 1 year high of $1,081.17.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share for the quarter, missing the consensus estimate of $8.46 by ($0.49). The firm had revenue of $3.15 billion for the quarter, compared to the consensus estimate of $3.19 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. Sell-side analysts anticipate that Regeneron Pharmaceuticals will post 37.23 EPS for the current year.

Insider Transactions at Regeneron Pharmaceuticals

In other news, CEO Leonard S. Schleifer sold 25,000 shares of the company’s stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total value of $24,481,250.00. Following the completion of the sale, the chief executive officer now directly owns 408,200 shares in the company, valued at approximately $399,729,850. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Leonard S. Schleifer sold 22,830 shares of the company’s stock in a transaction on Friday, May 17th. The shares were sold at an average price of $979.23, for a total value of $22,355,820.90. Following the completion of the transaction, the chief executive officer now owns 466,877 shares of the company’s stock, valued at approximately $457,179,964.71. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Leonard S. Schleifer sold 25,000 shares of the company’s stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total transaction of $24,481,250.00. Following the completion of the transaction, the chief executive officer now directly owns 408,200 shares of the company’s stock, valued at approximately $399,729,850. The disclosure for this sale can be found here. Insiders sold 61,971 shares of company stock worth $61,217,654 in the last three months. Corporate insiders own 7.48% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Sierra Summit Advisors LLC bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $1,011,000. Dynamic Technology Lab Private Ltd bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $749,000. Public Employees Retirement Association of Colorado boosted its holdings in shares of Regeneron Pharmaceuticals by 16.0% during the 4th quarter. Public Employees Retirement Association of Colorado now owns 16,074 shares of the biopharmaceutical company’s stock valued at $14,118,000 after purchasing an additional 2,220 shares during the last quarter. Exchange Traded Concepts LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 32.7% in the 4th quarter. Exchange Traded Concepts LLC now owns 4,954 shares of the biopharmaceutical company’s stock valued at $4,351,000 after acquiring an additional 1,221 shares during the last quarter. Finally, Congress Wealth Management LLC DE bought a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at about $271,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.